Gene Therapy Follow-Up: Balance Data Needs And Patient Burden, Bluebird Bio Exec Says

 
• By Kate Rawson
  
The FDA often requires 15 years of postmarket follow-up for approved gene therapies. (Shutterstock)

More from Cell & Gene Therapies

More from R&D